| dc.contributor.author |
Tzivras, M |
en |
| dc.contributor.author |
Balatsos, V |
en |
| dc.contributor.author |
Souyioultzis, S |
en |
| dc.contributor.author |
Tsirantonaki, M |
en |
| dc.contributor.author |
Skandalis, N |
en |
| dc.contributor.author |
Archimandritis, A |
en |
| dc.date.accessioned |
2014-06-06T06:43:19Z |
|
| dc.date.available |
2014-06-06T06:43:19Z |
|
| dc.date.issued |
1997 |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1016/S0149-2918(97)80044-6 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/1179 |
|
| dc.subject |
Duodenal Ulcer |
en |
| dc.subject |
helicobacter pylori |
en |
| dc.subject |
Side Effect |
en |
| dc.subject |
End of Treatment |
en |
| dc.subject |
Intent To Treat |
en |
| dc.subject |
Per Protocol |
en |
| dc.subject |
Proton Pump Inhibitor |
en |
| dc.title |
High eradication rate of Helicobacter pylori using a four-drug regimen in patients previously treated unsuccessfully |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1016/S0149-2918(97)80044-6 |
en |
| heal.publicationDate |
1997 |
en |
| heal.abstract |
The objective of this study was to assess the efficacy of a new regimen in eradicating Helicobacter pylori (Hp) in patients with duodenal ulcer (DU) who were previously treated unsuccessfully with standard triple therapy (tripotassium dicitratobismuthate [TDB] 120 mg QID, metronidazole 500 mg TID, and tetracycline 500 mg QID) or proton-pump inhibitor (PPI) dual therapy (omeprazole 20 mg BID and |
en |
| heal.journalName |
Clinical Therapeutics |
en |
| dc.identifier.doi |
10.1016/S0149-2918(97)80044-6 |
en |